Not yet recruiting NCT07231965
Synthetic THC And Blood Pressure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dronabinol, Placebo.
- Who it may be relevant to
- Registry conditions: Blood Pressure. Basic parameters: 21 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects Of Cannabis Products On Blood Pressure Control
Overview
To investigate the effects of Dronabinol use on blood pressure and neurovascular physiology
Interventions
- Drug Dronabinol
Patients will take one 10 mg dose of Dronabinol. - Drug Placebo
Patients will take one 10mg dose of a Placebo Pill.
Primary outcome measures
- Blood Pressure [Time frame: Baseline, 30 days]
- Heart Rate [Time frame: Baseline, 30 days]
Secondary outcome measures (4)
- Baroreflex Sensitivity [Time frame: Baseline, 30 days]
- Sympathetic control [Time frame: Baseline, 30 days]
- Flow Mediated Dilation [Time frame: Baseline, 30 days]
- Aortic Wave Reflection [Time frame: Baseline, 30 days]
Eligibility criteria
Inclusion criteria
- Recreational occasional Cannabis use (Consuming THC less than 2 times a week)
- 21 - 40 years of age
- Biological male or female
Exclusion criteria
- BMI > 35 kg/m2
- Diagnosed psychiatric disorders
- Hypotension
- History of seizures
- History of substance abuse or recreational drug use or positive urine drug screen
- History of uncontrolled disease including:
- Cardiovascular
- Pulmonary
- Gastrointestinal
- Pancreatic
- Hepatic
- Renal
- Hematological
- Endocrine (including Type I Diabetes)
- Neurological
- Urological
- Sleep disorders
- Pregnant or breastfeeding
- Use of certain antimicrobial, chemotherapeutic, anticoagulant, hypoglycemic, anti-inflammatory, psychotropic, and antihistamine drugs
- Prescribed CYP2C9 and/or CYP3A4 inhibitors
- History of shift work or rotating shifts within 1 month
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT07231965 · 25-008291